0A4U logo

BELLUS Health LSE:0A4U Stock Report

Last Price

CA$19.38

Market Cap

CA$2.5b

7D

0%

1Y

n/a

Updated

28 Jun, 2023

Data

Company Financials +

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

0A4U Stock Overview

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. More details

0A4U fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BELLUS Health Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BELLUS Health
Historical stock prices
Current Share PriceCA$19.38
52 Week HighCA$19.74
52 Week LowCA$10.22
Beta-0.28
1 Month Change-0.62%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change878.79%
Change since IPO1,213.01%

Recent News & Updates

Recent updates

Shareholder Returns

0A4UGB BiotechsGB Market
7D0%-5.0%-1.9%
1Yn/a-24.4%2.6%

Return vs Industry: Insufficient data to determine how 0A4U performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0A4U performed against the UK Market.

Price Volatility

Is 0A4U's price volatile compared to industry and market?
0A4U volatility
0A4U Average Weekly Movementn/a
Biotechs Industry Average Movement6.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0A4U has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0A4U's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
199374Roberto Belliniwww.bellushealth.com

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada.

BELLUS Health Inc. Fundamentals Summary

How do BELLUS Health's earnings and revenue compare to its market cap?
0A4U fundamental statistics
Market capCA$2.45b
Earnings (TTM)-CA$115.00m
Revenue (TTM)CA$19.88k

Over9,999x

P/S Ratio

-21.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4U income statement (TTM)
RevenueUS$15.00k
Cost of RevenueUS$0
Gross ProfitUS$15.00k
Other ExpensesUS$86.80m
Earnings-US$86.79m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.68
Gross Margin100.00%
Net Profit Margin-578,586.67%
Debt/Equity Ratio0%

How did 0A4U perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 18:08
End of Day Share Price 2023/06/21 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Justin ZelinBTIG
Pooya HemamiEdison Investment Research